Headlands Technologies LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Headlands Technologies LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,418 shares of the biopharmaceutical company’s stock, valued at approximately $642,000.

A number of other hedge funds have also added to or reduced their stakes in the business. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth about $29,000. Smartleaf Asset Management LLC boosted its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on HALO. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $63.02 on Thursday. The company has a market capitalization of $7.79 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00. The stock’s 50 day moving average is $59.62 and its 200-day moving average is $54.90.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,200 shares of company stock valued at $1,786,668. 2.90% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.